US Biomax, Inc.

PR753a

Prostate cancer and hyperplasia tissue array, including TNM and Gleason grade, 75 cases/75 cores, replacing PR753

Microarray Panel:Prostate carcinoma and hyperplasia tissue microarray, containing 64 cases of adenocarcinoma, 11 hyperplasia, single core per case
Cores:75
Cases:75
Layout:10 cols × 8 rows
Core Diameter:1.5 mm
Thickness:5 µm
Quality Control:H&E and IHC confirmed
Applications:

Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.

Notes:1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning.
2. Most of the TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). We still recommend 30 minutes of baking at 60°C before putting into xylene for de-paraffinization procedure.

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Gleason Grade TNM Type †
A1 1 M 26 Prostate Adenocarcinoma T2N0M0 Malignant
A2 2 M 57 Prostate Adenocarcinoma 2 T2N0M0 Malignant
A3 3 M 71 Prostate Adenocarcinoma 1 T2N0M0 Malignant
A4 4 M 63 Prostate Adenocarcinoma T3N0M0 Malignant
A5 5 M 66 Prostate Adenocarcinoma 2 T3N1M1 Malignant
A6 6 M 66 Prostate Adenocarcinoma 2 T2N0M0 Malignant
A7 7 M 60 Prostate Adenocarcinoma 2 T2N0M0 Malignant
A8 8 M 71 Prostate Adenocarcinoma 2–3 T2N0M0 Malignant
A9 9 M 73 Prostate Adenocarcinoma 3 T2N0M0 Malignant
A10 10 M 67 Prostate Adenocarcinoma 3 T2N0M1 Malignant
B1 11 M 75 Prostate Adenocarcinoma 1–2 T2N1M1C Malignant
B2 12 M 62 Prostate Adenocarcinoma 3 T3N0M0 Malignant
B3 13 M 76 Prostate Adenocarcinoma 2 T2AN0M0 Malignant
B4 14 M 64 Prostate Adenocarcinoma 3 T3N0M1 Malignant
B5 15 M 73 Prostate Adenocarcinoma 3 T3N0M0 Malignant
B6 16 M 69 Prostate Adenocarcinoma 3 T3N0M0 Malignant
B7 17 M 65 Prostate Adenocarcinoma 3 T2N0M0 Malignant
B8 18 M 73 Prostate Adenocarcinoma 3 T2N0M0 Malignant
B9 19 M 64 Prostate Adenocarcinoma 3 T2N0M0 Malignant
B10 20 M 72 Prostate Adenocarcinoma 4 T2N0M1 Malignant
C1 21 M 62 Prostate Adenocarcinoma 4 T2N0M0 Malignant
C2 22 M 65 Prostate Adenocarcinoma 3 T2N0M0 Malignant
C3 23 M 61 Prostate Adenocarcinoma 4 T2N0M0 Malignant
C4 24 M 60 Prostate Adenocarcinoma 2–3 T3N1M0 Malignant
C5 25 M 73 Prostate Adenocarcinoma 3 T3N0M0 Malignant
C6 26 M 71 Prostate Adenocarcinoma 3 T2N0M0 Malignant
C7 27 M 65 Prostate Adenocarcinoma 3 T2N0M0 Malignant
C8 28 M 56 Prostate Adenocarcinoma 3 T2N0M0 Malignant
C9 29 M 64 Prostate Adenocarcinoma 3 T2N0M0 Malignant
C10 30 M 70 Prostate Adenocarcinoma T3N0M0 Malignant
D1 31 M 75 Prostate Adenocarcinoma 3 T2N0M0 Malignant
D2 32 M 82 Prostate Adenocarcinoma 3 T2N0M0 Malignant
D3 33 M 76 Prostate Adenocarcinoma 4 T3N0M0 Malignant
D4 34 M 75 Prostate Adenocarcinoma 3 T3N0M0 Malignant
D5 35 M 69 Prostate Adenocarcinoma 4 T2N0M0 Malignant
D6 36 M 78 Prostate Adenocarcinoma 3 T4N0M0 Malignant
D7 37 M 75 Prostate Adenocarcinoma 2–3 T4N1M1 Malignant
D8 38 M 73 Prostate Adenocarcinoma 3 T3N1M0 Malignant
D9 39 M 64 Prostate Adenocarcinoma 4 T2AN0M0 Malignant
D10 40 M 82 Prostate Adenocarcinoma 3 T2N0M0 Malignant
E1 41 M 70 Prostate Adenocarcinoma 4 T3N0M0 Malignant
E2 42 M 64 Prostate Adenocarcinoma 3 T2N0M0 Malignant
E3 43 M 72 Prostate Adenocarcinoma 4 T3N0M0 Malignant
E4 44 M 56 Prostate Adenocarcinoma 4 T3N0M0 Malignant
E5 45 M 65 Prostate Adenocarcinoma 5 T2N0M0 Malignant
E6 46 M 87 Prostate Adenocarcinoma 4–5 T2N0M0 Malignant
E7 47 M 73 Prostate Adenocarcinoma 3 T2N0M0 Malignant
E8 48 M 60 Prostate Adenocarcinoma 5 T3N1M0 Malignant
E9 49 M 74 Prostate Adenocarcinoma 4 T4N1M1C Malignant
E10 50 M 82 Prostate Adenocarcinoma 5 T3N0M0 Malignant
F1 51 M 63 Prostate Adenocarcinoma 4 T2N0M0 Malignant
F2 52 M 82 Prostate Adenocarcinoma 5 T2N0M0 Malignant
F3 53 M 73 Prostate Adenocarcinoma 5 T4N0M0 Malignant
F4 54 M 66 Prostate Adenocarcinoma 5 T3AN0M0 Malignant
F5 55 M 60 Prostate Adenocarcinoma 5 T2N0M0 Malignant
F6 56 M 66 Prostate Adenocarcinoma 5 T2N0M0 Malignant
F7 57 M 80 Prostate Adenocarcinoma 4 T4N1M1C Malignant
F8 58 M 20 Prostate Adenocarcinoma 4 T3NOMO Malignant
F9 59 M 64 Prostate Adenocarcinoma 4 T2N0M0 Malignant
F10 60 M 68 Prostate Adenocarcinoma 5 T2N0M0 Malignant
G1 61 M 72 Prostate Adenocarcinoma 5 T3N0M0 Malignant
G2 62 M 78 Prostate Adenocarcinoma 4 T3N2M1 Malignant
G3 63 M 81 Prostate Adenocarcinoma 4 T3N0M0 Malignant
G4 64 M 77 Prostate Adenocarcinoma 5 T2N0M0 Malignant
G5 65 M 89 Prostate Hyperplasia Hyperplasia
G6 66 M 74 Prostate Hyperplasia Hyperplasia
G7 67 M 71 Prostate Hyperplasia Hyperplasia
G8 68 M 73 Prostate Hyperplasia Hyperplasia
G9 69 M 78 Prostate Hyperplasia Hyperplasia
G10 70 M 80 Prostate Hyperplasia Hyperplasia
H1 71 M 77 Prostate Hyperplasia Hyperplasia
H2 72 M 60 Prostate Hyperplasia Hyperplasia
H3 73 M 74 Prostate Hyperplasia Hyperplasia
H4 74 M 81 Prostate Hyperplasia Hyperplasia
H5 75 M 75 Prostate Hyperplasia Hyperplasia

† For precise diagnosis, refer to pathology description.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis


Find overlapping cases with this tissue array: